Pharmaceutical - Pharmaceutical, Licensing

Filter

Current filters:

PharmaceuticalLicensing

Popular Filters

1 to 25 of 760 results

EXPERT VIEW: Pay-for-delay - GSK’s wait is almost over…

EXPERT VIEW: Pay-for-delay - GSK’s wait is almost over…

22-08-2014

If GlaxoSmithKline thought that the demise of the Office of Fair Trading (OFT) on April 1 would bring…

Activist UK LimitedGenericsGlaxoSmithKlineLicensingPatentsPharmaceuticalSeroxatUK

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

20-08-2014

UK-based Clinigen Group has acquired the global rights to the oncology support therapy Ethyol (amifostine)…

ClinigenClinigen GroupEthyolLicensingOncologyPharmaceuticalTreatment for head and neck cancerUK

Provectus opens negotiations on licensing PV-10 in China

Provectus opens negotiations on licensing PV-10 in China

19-08-2014

US developmental stage company Provectus Biopharmaceuticals has entered into a memorandum of understanding…

Breast cancerChinaLicensingMemorandum of understandingOncologyPharmaceuticalProvectus BiopharmaceuticalsPV-10Sinopharm

Photocure and Salix terminate Lumacan partnership

Photocure and Salix terminate Lumacan partnership

18-08-2014

Norwegian photodynamic technologies specialist Photocure has agreed to terminate the global licensing…

Cosmo PharmaceuticalsLicensingLumacanNorwayOncologyPharmaceuticalPhotocurePhotodynamic technologies specialistSalix PharmaceuticalsUSA

Eisai teams up with Zeria on proton pump inhibitor license agreement

Eisai teams up with Zeria on proton pump inhibitor license agreement

18-08-2014

Japanese drug major Eisai has collaborated with fellow Japanese company Zeria Pharmaceutical to conclude…

EisaiGastro-intestinalsJapanLicensingPharmaceuticalProton pump inhibitorsZeria Pharmaceuticals

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

14-08-2014

China-based ZAI Lab has obtained global rights for two novel compounds from French pharma major Sanofi,…

Chronic lower respiratory diseasesGlobalLicensingPharmaceuticalRespiratory and PulmonarySanofiZAI Lab

Allergan acquires LiRIS program from TARIS Biomedical

Allergan acquires LiRIS program from TARIS Biomedical

14-08-2014

US drugmaker Allergan has closed a transaction to acquire worldwide rights to privately-held TARIS Biomedical’s…

AllerganGenito-urinaryGlobalLicensingLiRISPharmaceuticalTARIS Biomedical

RedHill and RESprotect sign exclusive deal over cancer drug

RedHill and RESprotect sign exclusive deal over cancer drug

14-08-2014

Israeli biotech firm RedHill Biopharma and privately-held German biotech company RESprotect GmbH have…

Dror Ben-AsherGermanyIsraelLicensingOncologyPancreatic cancerPharmaceuticalRedHill BiopharmaRESprotectSouth Korea

Boehringer Ingelheim acquires licensing rights for Artilysin technology

Boehringer Ingelheim acquires licensing rights for Artilysin technology

13-08-2014

Artilysin, a new and innovative technological approach in the fight against pathogenic and multi-resistant…

Antibiotics and Infectious diseasesArtilysinBoehringer IngelheimGermanyLicensingLysando AGPharmaceutical

Sanofi in $925 million deal to commercialize MannKind’s Afrezza

Sanofi in $925 million deal to commercialize MannKind’s Afrezza

11-08-2014

French pharma major Sanofi has entered into a worldwide exclusive licensing agreement with the USA’s…

AfrezzaDiabetesGlobalInsulin therapyLicensingMannKindPeptide hormonesPharmaceuticalSanofi

Cancer Research UK and Astellas join forces on pancreatic cancer treatment

09-08-2014

Japanese drug major Astellas Pharma is joining forces with Cancer Research UK and its commercial arm,…

Astellas PharmaCancer Research TechnologyLicensingOncologyPharmaceuticalResearch

OX-MPI project returned to Orexo

OX-MPI project returned to Orexo

08-08-2014

Swedish drug developer Orexo says that German family-owned pharma major Boehringer Ingelheim has decided…

Boehringer IngelheimGermanyLicensingOrexo ABPharmaceuticalProstaglandin ESweden

Daiichi Sankyo and Charleston Laboratories sign collaboration deal worth up to $650 million

Daiichi Sankyo and Charleston Laboratories sign collaboration deal worth up to $650 million

07-08-2014

Japanese drug major Daiichi Sankyo and privately-held Charleston Laboratories, through its wholly owned…

AnalgesiaCharleston LaboratoriesDaiichi SankyoHydrocodone combination productsJapanLicensingMorphinansPharmaceuticalUSA

Ariad enlists Medison to market Iclusig in Israel

Ariad enlists Medison to market Iclusig in Israel

06-08-2014

US specialty pharma firm Ariad Pharmaceuticals has granted Israel’s Medison Pharma exclusive rights…

AlkynesAriad PharmaceuticalsIclusigIsraelLicensingOncologyOrganofluoridesPharmaceuticalPiperazines

Medivir licenses RSV program from Boehringer Ingelheim

Medivir licenses RSV program from Boehringer Ingelheim

05-08-2014

Swedish drugmaker Medivir has entered a license agreement with German family-owned pharma major Boehringer…

Boehringer IngelheimGlobalHuman respiratory syncytial virusLicensingMedivirMononegaviralesPharmaceuticalRespiratory and PulmonaryViral diseases

THERAMetrics and Centurion Pharma collaboration in rare diseases area

THERAMetrics and Centurion Pharma collaboration in rare diseases area

05-08-2014

Switzerland’s THERAMetrics holding and Turkish drugmaker Centurion Pharma plan to cooperate in the…

aviptadilCenturion PharmaIdiopathic pulmonary fibrosisLicensingPharmaceuticalRaffaele PetroneRare diseasesSarcoidosisTHERAMetricsTurkey

Ziopharm and Solasia amend collaboration for darinaparsin

Ziopharm and Solasia amend collaboration for darinaparsin

01-08-2014

US drug developer Ziopharm Oncology and Japan’s Solasia Pharma, a developer of oncology pharmaceuticals…

darinaparsinGlobalLicensingOncologyPharmaceuticalSolasia PharmaZinaparZiopharm Oncology

Durata out-licenses dalbavancin to Angelini for certain territories

Durata out-licenses dalbavancin to Angelini for certain territories

30-07-2014

USA-based Durata Therapeutics says its Dutch subsidiary entered into a license and supply agreement with…

AngeliniAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsEuropeLicensingPharmaceutical

PaxVax acquires the FDA-approved typhoid vaccine Vivotif

PaxVax acquires the FDA-approved typhoid vaccine Vivotif

29-07-2014

Privately-held California, USA-based specialty vaccine firm PaxVax says it has acquired the oral typhoid…

LicensingMergers & AcquisitionsPaxVaxPharmaceuticalProductionSwitzerlandVaccinesVivotif

Ono and Meiji Seika make development and commercialization agreement on Limaprost

Ono and Meiji Seika make development and commercialization agreement on Limaprost

29-07-2014

Japanese companies Ono Pharmaceutical and Meiji Seika have announced an agreement on the development…

IndonesiaJapanLicensinglimaprostMedicineMeiji Seika PharmaOncologyOno PharmaceuticalPharmaceuticalSpinal stenosisThailand

Roche joins forces with AmorChem on Steinert’s disease research

Roche joins forces with AmorChem on Steinert’s disease research

29-07-2014

Swiss drug major Roche and AmorChem, a Canadian venture capital firm investing in life science projects,…

AmorChemCanadaEnabling technologyEuropean UnionLicensingMajorMuscular dystrophyMyotonic dystrophyPharmaceuticalRare diseasesResearchRocheSwitzerland

Zealand and Boehringer link up to advance novel peptide medicines

Zealand and Boehringer link up to advance novel peptide medicines

28-07-2014

Denmark’s Zealand Pharma has entered into a new global exclusive licence and R&D collaboration with…

Boehringer IngelheimCardio-vascularDenmarkFinancialGermanyLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Ranbaxy to distribute Cipher’s isotretinoin product in Brazil

25-07-2014

Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s…

BrazilCipher PharmaceuticalsDermatologicalsIsotretinoinLicensingPharmaceuticalRanbaxy Laboratories

Bristol-Myers and Ono Pharma enter Asia oncology accord

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabMelanomaOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

1 to 25 of 760 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top